drugset / Trial / NCT04332523
A Study of JNJ-53718678 in Participants With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of the study is to evaluate the pharmacokinetc (PK) of a single oral dose of JNJ-53718678 in participants with varying degrees of impaired hepatic function (mild, moderate, and severe) when compared with participants with normal hepatic function.
Timeline
- Start
- 2020-08-17
- Primary completion
- 2022-03-16
- Completion
- 2022-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rilematovir | Other / unclassified | — | Oral |
Indications
No indication recorded.